<DOC>
	<DOCNO>NCT01965912</DOCNO>
	<brief_summary>The study single-cohort , interventional , open-label trial evaluate long-term neurocognitive ( NC ) outcomes child age 4 5 year phenylketonuria ( PKU ) treat Kuvan® Phenylalanine-restricted diet period 7 year .</brief_summary>
	<brief_title>Kuvan® 's Effect Cognition Children With Phenylketonuria</brief_title>
	<detailed_description />
	<mesh_term>Phenylketonurias</mesh_term>
	<mesh_term>Verapamil</mesh_term>
	<criteria>Male female outpatient , 4 5 year age ( great equal 4 less 6 ) time informed consent form signature parent ( ) guardian ( ) Confirmed clinical biochemical diagnosis PKU , include least two separate blood phenylalanine level great equal 400 micromole per liter ( mcmol/L ) Defined preKuvan®/tetrahydrobiopterin ( BH4 ) dietary phenylalanine tolerance consistent diagnosis PKU Responsive Kuvan®/BH4 : For subject currently treat Kuvan®/BH4 Screening : subject responder per Investigator judgment base documented effect Kuvan®/BH4 phenylalanine level and/or phenylalanine tolerance For subject treat Kuvan®/BH4 Screening : response test perform Screening available subject 's medical record satisfies 3 follow criterion : decrease blood phenylalanine level least 30 percent observe least 24 hour dose least 10 mg/kg/day Intelligence Quotient ( IQ ) great equal 70 , assess Wechsler Preschool Primary Scale Intelligence ( WPPSI ) III , 2nd part Good adherence dietary treatment ( include prescribe dietary phenylalanine restriction prescribe amount phenylalaninefree protein supplement lowphenylalanine food ) , assess Investigator Wellcontrolled phenylalanine level , assess minimum 75 percent phenylalanine level within target recommend centre previous 3 month Low phenylalanine diet start within first 3 week life Parent ( ) guardian ( ) willing comply study procedure , maintain strict adherence diet , willing able provide write , sign informed consent trialrelated activity carry , well ability child comply trial procedure Known hypersensitivity Kuvan® excipients Known hypersensitivity approve nonapproved formulation BH4 Previous diagnosis BH4 deficiency Current use methotrexate , trimethoprim dihydrofolate reductase inhibitor Current use medication know affect nitric oxide synthesis , metabolism action Current use experimental unregistered drug ( sapropterin/BH4 ) may affect study outcome use agent within 30 day prior Screening Concurrent use levodopa Concurrent disease condition would induce repeatedly catabolic situation , interfere trial participation , diet , NC development , assess Investigator Any condition , view Investigator , render subject high risk failure comply treatment complete trial Participation clinical trial investigate agent Kuvan® within past 30 day</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>5 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Phenylketonuria</keyword>
	<keyword>Kuvan</keyword>
	<keyword>Sapropterin dihydrochloride</keyword>
</DOC>